Classical Hodgkin lymphoma, pediatric - historical

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main pediatric Hodgkin lymphoma page for current regimens.

Last updated on 2024-07-23:
7 regimens on this page
10 variants on this page


Untreated

ABVE

ABVE: Adriamycin (Doxorubicin), Bleomycin, Vincristine, Etoposide

Regimen

Study Dates of enrollment Evidence
Tebbi et al. 2012 (POG P9426) 1996-2001 Non-randomized (see note)

Note: this trial had a randomization to receive or not receive dexrazoxane. Labeled here as non-randomized because this drug does not have antineoplastic properties.

Chemotherapy

Supportive therapy

  • Filgrastim (Neupogen) 5 mcg/kg SC once per day on days 6 to 14, then once per day on days 16 until ANC greater than 1000/μL

28-day cycle for 2 cycles

Subsequent treatment

  • POG P9426, CR: IFRT consolidation
  • POG P9426, other than CR: ABVE x 2, then IFRT consolidation

References

  1. POG P9426: Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ, de Alarcón PA, Schwartz C, Chauvenet A. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Dec 15;59(7):1259-65. Epub 2012 Aug 21. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00002827


ABVE-PC

ABVE-PC: Adriamycin (Doxorubicin), Bleomycin, Vincristine, Etoposide, Prednisone, Cyclophosphamide

Regimen

Study Evidence
Schwartz et al. 2009 (POG P9425) Phase 2

Note: This regimen is intended for pediatric patients, younger than 22 years old. Note that first day of chemotherapy is day 0. Bleomycin and prednisone dosing is post-amendment.

Chemotherapy

Glucocorticoid therapy

Supportive therapy

21-day cycle for varying durations: 3 cycles (POG P9425; rapid early responders); 5 cycles (POG P9425; slow early responders)

Subsequent treatment

  • IFRT consolidation x 2100 cGy

References

  1. POG P9425: Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, Lipshultz SE, Turner CS, deAlarcon PA, Chauvenet A. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009 Sep 3;114(10):2051-9. Epub 2009 Jul 7. Erratum: in Blood 2016 128:605 link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00005578


MOPP

MOPP: Mechlorethamine, Oncovin (Vincristine), Procarbazine, Prednisone

Regimen

Study Dates of enrollment Evidence
Young et al. 1973a 1964 to not reported Non-randomized (RT)
Kolygin 1976 1970-1975 Non-randomized (RT)

Chemotherapy

Glucocorticoid therapy

28-day cycle for 6 to 8 cycles

References

  1. Young RC, DeVita VT, Johnson RE. Hodgkin's disease in childhood. Blood. 1973 Aug;42(2):163-74. link to original article PubMed
  2. Kolygin BA. Combination chemotherapy of Hodgkin's disease in children. Cancer. 1976 Oct;38(4):1494-7. link to original article PubMed


OPPA

OPPA: Oncovin (Vincristine), Procarbazine, Prednisone, Adriamycin (Doxorubicin)

Regimen

Study Dates of enrollment Evidence
Mauz-Körholz et al. 2010 (GPOH-HD-2002) 2002-2005 Phase 2

Note: This regimen is meant for girls. Patients with early-stage disease only received the OPPA portion, see text for details.

Chemotherapy

Glucocorticoid therapy

28-day cycle for 2 cycles

Subsequent treatment

  • GPOH-HD-2002, treatment group 2: COPP consolidation x 2
  • GPOH-HD-2002, treatment group 3: COPP consolidation x 4

References

  1. GPOH-HD-2002: Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00416832


VAMP (Methotrexate)

VAMP: Vinblastine, Adriamycin (Doxorubicin), Methrotrexate, Prednisone

Regimen

Study Dates of enrollment Evidence
Metzger et al. 2012 (HOD99) 2000-03-03 to 2008-12-09 Phase 2

Note: This is to be distinguished from the VAMP protocols used in AML and multiple myeloma.

Chemotherapy

Glucocorticoid therapy

28-day cycle for 4 cycles

Subsequent treatment

References

  1. HOD99: Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, Howard SC, Donaldson SS, Krasin MJ, Kun LE, Marcus KJ, Yock TI, Tarbell N, Billups CA, Wu J, Link MP. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012 Jun 27;307(24):2609-16. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed


Consolidation after upfront therapy

C-MOPP

C-MOPP: CyclophosphaMide, Oncovin (Vincristine), Procarbazine, Prednisone
COPP: Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone

Regimen variant #1, 2 cycles

Study Dates of enrollment Evidence
Mauz-Körholz et al. 2010 (GPOH-HD-2002) 2002-2005 Phase 2

Preceding treatment

Chemotherapy

Glucocorticoid therapy

28-day cycle for 2 cycles


Regimen variant #2, 4 cycles

Study Dates of enrollment Evidence
Mauz-Körholz et al. 2010 (GPOH-HD-2002) 2002-2005 Phase 2

Preceding treatment

Chemotherapy

Glucocorticoid therapy

28-day cycle for 4 cycles

References

  1. GPOH-HD-2002: Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00416832


COPDAC

COPDAC: Cyclophosphamide, Oncovin (Vincristine), Prednisone, DACarbazine

Regimen variant #1, 2 cycles

Study Dates of enrollment Evidence
Mauz-Körholz et al. 2010 (GPOH-HD-2002) 2002-2005 Phase 2

Preceding treatment

Chemotherapy

Glucocorticoid therapy

28-day cycle for 2 cycles


Regimen variant #2, 4 cycles

Study Dates of enrollment Evidence
Mauz-Körholz et al. 2010 (GPOH-HD-2002) 2002-2005 Phase 2

Preceding treatment

Chemotherapy

Glucocorticoid therapy

28-day cycle for 4 cycles

References

  1. GPOH-HD-2002: Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00416832